Organization | Grupo Mexicano para el Estudio de la Medicina Intensiva

Grupo Mexicano para el Estudio de la Medicina Intensiva Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial

2018

NCT03784794

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2020

Timeline

NOW

Now

Alternative names

Angel Augusto Perez Calatayud | Grupo Mexicano para el Estudio de la Medicina Intensiva | Head Obstetric ICU

Active Ingredients

Drugs in Phase 2 Trials (1)

COVID-19 convalescent plasma (1 trial)

Drugs in Other Trials (7)

alteplase (Activase) (1 trial)

blood plasma (1 trial)

cryoprecipitate (1 trial)

fibrinogen (human) (RiaSTAP) (1 trial)

human factor ix complex (prothrombin complex concentrate) (Kcentra) (1 trial)

platelets (1 trial)

red blood cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Pneumonia (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 3
# of Trial APIs: 8